Trial site
CIONC-Centro Integrado de Oncologia de Curitiba
Curitiba, 80810-050, BrazilNot linked to an institution yet
- 10running trials
- 1closed trial
The trials here
What the 11 trials at this site are about, from their registry records.
- Phase
- Phase 37 trials
- Phase 1/22 trials
- Phase 21 trial
- Phase 2/31 trial
- Status
- Active, not recruiting7 trials
- Recruiting3 trials
- Terminated1 trial
- Lead sponsor
- Janssen Research & Development, LLC5 trials
- Daiichi Sankyo2 trials
- Amgen1 trial
- BioNTech SE1 trial
- Incyte Corporation1 trial
- and 1 more
Running trials
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)
NCT06712316· Phase 2/3· BioNTech SE· Source
Active, not recruiting
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
NCT06311721· Phase 3· Amgen· Source
Recruiting
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
NCT05950945· Phase 3· Daiichi Sankyo· Source
Contact: Study Coordinator
Active, not recruiting
A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer
NCT05908734· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer
NCT05488314· Phase 1/2· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
NCT05253651· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source
Active, not recruiting
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
NCT04988295· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)
NCT04497844· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer
NCT03748641· Phase 3· Janssen Research & Development, LLC· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error